Clinical Trial Detail

NCT ID NCT02410512
Title A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

Therapies

MOXR0916

Atezolizumab

Age Groups: adult

No variant requirements are available.